Hemab Therapeutics Holdings
COAG
28.70
+0.33
+1.16%
Hemab Therapeutics Holdings
US · COAG
#3007 by market cap
Listed 2026
28.70
+0.33
+1.16%
Live - 5344 symbols - heartbeat 493s ago
· 2026-10-08 02:52
After-hours
28.70
0.00%
Overnight
28.37
-1.15%
- Market cap
- 1.34B
- P/E (TTM)i
- -16.11
- P/Bi
- 2.95
- EPSi
- -1.45
- Div yieldi
- 0.00%
- 52W posi
- 18%
Reader sentiment
Are you bullish or bearish on COAG?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Accumulating
- The number of reporting institutions decreased by 1 in the most recent period (2026/Q3).
- Total institutional ownership rose 0.5 percentage points.
Institutional ownership
- Held by institutions
- 101.07% +0.52pp
- Institutions
- 62 -1
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
VC/PE Fund61.69%
Mutual Fund26.64%
Hedge Fund12.58%
Individual/Insider0.26%
Top holders as of 2026-06-30
RA Capital Management, L.P.
16.72% · 7.81M sh
Access Biotechnology
10.44% · 4.88M sh
Novo Holdings A/S
8.95% · 4.18M sh
FMR
7.92% · 3.70M sh
Capital Research
7.72% · 3.60M sh
Deep Track Capital, LP
7.71% · 3.60M sh
Avoro Capital Advisors LLC
7.06% · 3.30M sh
Sofinnova Partners SAS
5.38% · 2.51M sh
Artal Group S.A.
4.91% · 2.30M sh
Odlander, Fredrikson & Co. AB
4.06% · 1.89M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
29 filings tracked · 15 buys · 0 sells
| Name | Role | Stake |
|---|---|---|
| RA Capital Management, L.P. | -- | 16.72% |
| Access Biotechnology | -- | 10.44% |
| Mads Behrndt-Eriksen | CFO & GM | 0.19% |
| John Michael Maraganore | Independent Chairperson | 0.08% |
| Novo Holdings A/S | -- | -- |
| Akshay Vaishnaw | Independent Director | -- |
| Linda Bain | Independent Director | -- |
| Benny Sorensen | Chief Executive Officer | -- |
| Keli Walbert | Director | -- |
| Catherine Madigan | Chief Medical Officer | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-23 | Keli Walbert | Director | Other Derivative Acquisition | +36,000 | $35.72 |
| 2026-06-15 | RA Capital Management, L.P. | -- | Open Market Acquisition | +67,669 | $24.89–24.98 |
| 2026-05-19 | RA Capital Management, L.P. | -- | Open Market Acquisition | +4,798 | $24.94–24.97 |
| 2026-05-11 | RA Capital Management, L.P. | -- | Open Market Acquisition | +6,387 | $24.90 |
| 2026-05-10 | RA Capital Management, L.P. | -- | Open Market Acquisition | +51,258 | $24.34–25.00 |
| 2026-05-05 | RA Capital Management, L.P. | -- | Open Market Acquisition | +165,429 | $23.77–25.00 |
| 2026-05-03 | John Michael Maraganore | Independent Chairperson | Derivative Exercise and Retained | +35,948 | -- |
| 2026-05-03 | Novo Holdings A/S | -- | Derivative Exercise and Retained | +4,180,550 | -- |
| 2026-05-03 | RA Capital Management, L.P. | -- | Private Acquisition | +2,675,000 | $18.00 |
| 2026-05-03 | RA Capital Management, L.P. | -- | Derivative Exercise and Retained | +4,838,086 | -- |
| 2026-05-03 | Access Biotechnology | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-04-29 | John Michael Maraganore | Independent Chairperson | Initial Statement of Beneficial | 0 | -- |
| 2026-04-29 | Novo Holdings A/S | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-04-29 | Akshay Vaishnaw | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-04-29 | Linda Bain | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-04-29 | Benny Sorensen | Chief Executive Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-04-29 | Catherine Madigan | Chief Medical Officer | Other Derivative Acquisition | +49,016 | $18.00 |
| 2026-04-29 | Catherine Madigan | Chief Medical Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-04-29 | Mads Behrndt-Eriksen | CFO & GM | Other Derivative Acquisition | +49,016 | $18.00 |
| 2026-04-29 | Mads Behrndt-Eriksen | CFO & GM | Initial Statement of Beneficial | 0 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 02:52:22 · For reference only, not investment advice and not tailored to your situation.